神冠控股(00829.HK)年度純利跌6%至7544.4萬元 擬派息6港仙
格隆匯3月30日丨神冠控股(00829.HK)公佈,截至2019年12月31日止年度,集團實現收入9.98億元(人民幣,下同),同比增10.95%;毛利2.32億元,同比減少25.71%;公司擁有人應占盈利7544.4萬元,同比減少6.00%;基本每股盈利2.3分;擬派發末期股息每股2.0港仙及特別末期股息每股4.0港仙。
儘管受非州豬瘟疫情的影響,2019年度的膠原蛋白腸衣的銷售量比上年度仍有增加。毛利率由上年度約34.8.%下降至本年度約23.3%。毛利率下降的主要原因是腸衣的生產成本及試製成本增加。
集團致力於加強膠原蛋白技術的開發,並以打造安全、可靠、標準化的大健康產業為目標,實現膠原蛋白產業轉型升級及積極推動膠原蛋白在大健康產業方面的應用。集團於膠原蛋白食品、保健品、護膚品、醫療用品等方面正在努力開展新技術及新產品的研發,惟新產品研發成功並上市銷售具有不確定性,需要花費大量的時間才能達到預期目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.